Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Itraconazole Effect on Lurbinectedin PK in Advanced Solid Tumors
NCT05063318Phase 1Completed
- Sponsor
- PharmaMar
- Start
- Oct 2020
- Primary completion
- Apr 2022
- Modality
- Classical Binding Small Molecules, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of lurbinectedin in solid tumor (advanced stage) (2 arms), sponsored by PharmaMar. Primary endpoint: Dose-adjusted Area Under the Curve from time zero to infinity. Started Oct 2020; status: completed.
02
Drugs
lurbinectedin
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05063318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05063318.